Recombinant DMA Advisory Committee - 6/9-10/94 
Robert Overell, Targeted Genetics Corporation 
Andrea Pavirani, Transgene, Inc. 
Michael Penn, Genetic Therapy, Inc. 
Michael Pensiero, Genetic Therapy, Inc. 
Jerri Perkins, Perkins & Perkins 
Joan Personett, American College of Obstetricians and Gynecologists 
Stephen Pijar, University of Maryland 
Chi^ Platsoucas, Temple University School of Medicine 
John Powderly, Georgetown Medical School 
Raj Puri, Food and Drug Administration 
Kathryn Pushkar, The Blue Sheet 
Urban Ramstedt, Virus Research Institute 
Thomas Reynolds, Targeted Genetics Corporation 
Rex Rhein, Biotechnology Newswatch 
Paul Robbins, University of Pittsburgh 
Jack Roth, MD Anderson Cancer Center 
Leonard Schiff, Microbiological Associates, Inc. 
Richard Scotland, Genzyme Corporation 
Tomiko Shimada, Ambience Awareness International 
John Shiver, Merck, Inc. 
Robert Sobol, San Diego Regional Cancer Center 
Ruth SoRelle, Houston Chronicle 
Margi Stuart, Breast Cancer Action 
Frank Sturtz, Progenitor, Inc. 
Hideaki Tahara, University of Pittsburgh 
Tom Tarlow, Chiron Corporation 
Paul Tolstoshev, Genetic Therapy, Inc. 
Matthew Tomaino, University of Pittsburgh 
Karl Uhlendorf, The Blue Sheet 
Cynthia Utley, GenVec 
Dominick Vacante, Microbiological Associates, Inc. 
Deborah Vaz, Virus Research Institute 
Wanda de Vlaminck, Avigen, Inc. 
Kermeth Walsh, St. Elizabeth Medical Center 
Judi Weissinger, Applied Immune Sciences 
Katharine Whartenby, Food and Drug Adminstration 
Sharon Williams, life Technologies, Inc. 
Wei-Wei Zhang, MD Anderson Cancer Center 
Laurence Zitvogel, University of Pittsburgh 
[312] 
Recombinant DNA Research, Volume 19 
